336 related articles for article (PubMed ID: 26749488)
1. Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.
Song HN; Jung KS; Yoo KH; Cho J; Lee JY; Lim SH; Kim HS; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Park W; Ahn MJ
J Thorac Oncol; 2016 Apr; 11(4):e45-7. PubMed ID: 26749488
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGFR
Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
[TBL] [Abstract][Full Text] [Related]
3. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
[TBL] [Abstract][Full Text] [Related]
4. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
5. Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas.
Jukna A; Montanari G; Mengoli MC; Cavazza A; Covi M; Barbieri F; Bertolini F; Rossi G
J Thorac Oncol; 2016 Apr; 11(4):e49-51. PubMed ID: 26746366
[TBL] [Abstract][Full Text] [Related]
6. EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance.
Wang S; Song Y; Liu D
Cancer Lett; 2017 Jan; 385():51-54. PubMed ID: 27840244
[TBL] [Abstract][Full Text] [Related]
7. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.
Tseng JS; Su KY; Yang TY; Chen KC; Hsu KH; Chen HY; Tsai CR; Yu SL; Chang GC
Oncotarget; 2016 Jul; 7(30):48059-48069. PubMed ID: 27384480
[TBL] [Abstract][Full Text] [Related]
8. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
Wu SG; Liu YN; Tsai MF; Chang YL; Yu CJ; Yang PC; Yang JC; Wen YF; Shih JY
Oncotarget; 2016 Mar; 7(11):12404-13. PubMed ID: 26862733
[TBL] [Abstract][Full Text] [Related]
10. Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.
Yu HA; Tian SK; Drilon AE; Borsu L; Riely GJ; Arcila ME; Ladanyi M
JAMA Oncol; 2015 Oct; 1(7):982-4. PubMed ID: 26181354
[No Abstract] [Full Text] [Related]
11. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y
Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161
[TBL] [Abstract][Full Text] [Related]
12. Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance.
Patel H; Pawara R; Ansari A; Surana S
Eur J Med Chem; 2017 Dec; 142():32-47. PubMed ID: 28526474
[TBL] [Abstract][Full Text] [Related]
13. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
14. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
15. First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
Ma Y; Zheng X; Zhao H; Fang W; Zhang Y; Ge J; Wang L; Wang W; Jiang J; Chuai S; Zhang Z; Xu W; Xu X; Hu P; Zhang L
J Thorac Oncol; 2018 Jul; 13(7):968-977. PubMed ID: 29626621
[TBL] [Abstract][Full Text] [Related]
16. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
17. There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.
Clery E; Pisapia P; Feliciano S; Vigliar E; Marano A; De Luca C; Malapelle U; Troncone G; Bellevicine C
J Clin Pathol; 2017 Sep; 70(9):798-802. PubMed ID: 28363898
[TBL] [Abstract][Full Text] [Related]
18. Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors.
Li C; Liu H; Zhang B; Gong L; Su Y; Zhang Z; Wang C
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1079-1086. PubMed ID: 29616327
[TBL] [Abstract][Full Text] [Related]
19. Rociletinib in EGFR-mutated non-small-cell lung cancer.
Sequist LV; Soria JC; Goldman JW; Wakelee HA; Gadgeel SM; Varga A; Papadimitrakopoulou V; Solomon BJ; Oxnard GR; Dziadziuszko R; Aisner DL; Doebele RC; Galasso C; Garon EB; Heist RS; Logan J; Neal JW; Mendenhall MA; Nichols S; Piotrowska Z; Wozniak AJ; Raponi M; Karlovich CA; Jaw-Tsai S; Isaacson J; Despain D; Matheny SL; Rolfe L; Allen AR; Camidge DR
N Engl J Med; 2015 Apr; 372(18):1700-9. PubMed ID: 25923550
[TBL] [Abstract][Full Text] [Related]
20. Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance.
Wang Z; Yang JJ; Huang J; Ye JY; Zhang XC; Tu HY; Han-Zhang H; Wu YL
J Thorac Oncol; 2017 Nov; 12(11):1723-1727. PubMed ID: 28662863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]